Effects of Epidermal Growth Factor and Linoleic Acid on Lipid Contents in Human Intestinal C2BBe1 Cells

Liang, Chiu-Fang; Chao, Jane C J; Hwang, Shiaw-Min; Tsai, Yu-Chen

doi:10.1080/15216540215683

Cited by 3 publications

(3 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…EGF is reported to regulate the secretion and formation of lipids in cells, and triglyceride secretion in Caco-2 colon cancer cells is stimulated by EGF . EGF also increases the intracellular cholesterol and triglyceride levels in C2BBel colon cancer cells . Therefore, we suggest that broadening of the Raman band at 1662 cm –1 occurs as a result of EGF-induced increases in triglyceride and cholesterol levels in cells.…”

Section: Resultsmentioning

confidence: 69%

“…52 EGF also increases the intracellular cholesterol and triglyceride levels in C2BBel colon cancer cells. 53 Therefore, we suggest that broadening of the Raman band at 1662 cm −1 occurs as a result of EGF-induced increases in triglyceride and cholesterol levels in cells. These results show for the first time that noninvasive Raman spectroscopy efficiently detects the effects of EGF−EGFR binding on subcellular components.…”

Section: ■ Results and Discussionmentioning

confidence: 80%

See 1 more Smart Citation

Label-Free Raman Spectroscopic Imaging Monitors the Integral Physiologically Relevant Drug Responses in Cancer Cells

et al. 2015

View full text Add to dashboard Cite

Predictions about the cellular efficacy of drugs tested in vitro are usually based on the measured responses of a few proteins or signal transduction pathways. However, cellular proteins are highly coupled in networks, and observations of single proteins may not adequately reflect the in vivo cellular response to drugs. This might explain some large discrepancies between in vitro drug studies and drug responses observed in patients. We present a novel in vitro marker-free approach that enables detection of cellular responses to a drug. We use Raman spectral imaging to measure the effect of the epidermal growth factor receptor (EGFR) inhibitor panitumumab on cell lines expressing wild-type Kirsten-Ras (K-Ras) and oncogenic K-Ras mutations. Oncogenic K-Ras mutation blocks the response to anti-EGFR therapy in patients, but this effect is not readily observed in vitro. The Raman studies detect large panitumumab-induced differences in vitro in cells harboring wild-type K-Ras as seen in A in red but not in cells with K-Ras mutations as seen in B; these studies reflect the observed patient outcomes. However, the effect is not observed when extracellular-signal-regulated kinase phosphorylation is monitored. The Raman spectra show for cells with wild-type K-Ras alterations based on the responses to panitumumab. The subcellular component with the largest spectral response to panitumumab was lipid droplets, but this effect was not observed when cells harbored K-Ras mutations. This study develops a noninvasive, label-free, in vitro vibrational spectroscopic test to determine the integral physiologically relevant drug response in cell lines. This approach opens a new field of patient-centered drug testing that could deliver superior patient therapies.

show abstract